Cyclopharm Ltd

CYC

Company Profile

  • Business description

    Cyclopharm Ltd is a health technology company offering solutions related to functional lung ventilation imaging. Its proprietary product Technegas is a broad-spectrum diagnostic lung imaging technology product for the visualisation of pulmonary ventilation and lung function. The company sells its products to healthcare institutions and medical professionals. Maximum revenue is generated from its Technegas products and services, which include the sale of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. Geographically, the company generates maximum revenue from its business in Europe, and the rest from Asia Pacific, Canada, the USA, and other regions.

  • Contact

    1 The Crescent
    Unit 4
    Kingsgrove
    SydneyNSW2208
    AUS

    T: +61 295410411

    https://cyclopharm.com.au

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Medical Distribution

    Fiscal Year End

    31 December 2026

    Employees

    109

Stocks News & Analysis

stocks

Beaten down real estate share receives legal blow

Real estate share remains cheap despite losing airport legal battle.
stocks

OpenAI joins the mega-AI lab IPO race, but timing is uncertain

The ChatGPT maker joined Anthropic in filing a confidential S-1 with the SEC, teeing up a future IPO.
stocks

What happens if Tesla and SpaceX merge?

We see a solid business case for a merger, but not without hurdles, including Tesla shareholders’ concern about SpaceX’s valuation.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,006.1029.100.32%
CAC 408,350.87150.081.83%
DAX 4024,635.30425.591.76%
Dow JONES (US)51,202.26353.510.70%
FTSE 10010,471.72167.841.63%
HKSE24,718.10468.811.93%
NASDAQ25,888.8479.180.31%
Nikkei 22566,020.041,802.772.81%
NZX 50 Index13,393.87191.711.45%
S&P 5007,431.4637.160.50%
S&P/ASX 2008,804.0030.500.35%
SSE Composite Index4,031.5144.501.12%

Market Movers